DiscoverTuesday Night IBSAmitriptyline and Ondansetron for Irritable Bowel Syndrome: Efficacy data from the ground breaking studies
Amitriptyline and Ondansetron for Irritable Bowel Syndrome: Efficacy data from the ground breaking studies

Amitriptyline and Ondansetron for Irritable Bowel Syndrome: Efficacy data from the ground breaking studies

Update: 2024-06-21
Share

Description

On this special episode of Tuesday Night IBS, we talk with the co-principal investigator, Alex Ford, MD, from Leeds University in the UK, about the ATLANTIS trial of Amitriptyline for irritable bowel syndrome (IBS) in primary care, which was funded by the Health Technology Assessment program of the National Institute for Health and Care Research and the TRITON trial using Ondansetron to manage irritable bowel syndrome with diarrhea.

Dr. Alex Ford is a Professor and Honorary consultant gastroenterologist at St. James’s University Hospital, Leeds, UK. His main interest is in the epidemiology, diagnosis, and treatment of disorders of gut-brain interaction, such as irritable bowel syndrome and functional dyspepsia. He is an Associate Editor for Alimentary Pharmacology & Therapeutics. He has published over 450 peer-reviewed articles, including original scientific papers in The Lancet, JAMA, BMJ, Gastroenterology, Gut, Archives of Internal Medicine, and The American Journal of Gastroenterology.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Amitriptyline and Ondansetron for Irritable Bowel Syndrome: Efficacy data from the ground breaking studies

Amitriptyline and Ondansetron for Irritable Bowel Syndrome: Efficacy data from the ground breaking studies

Jeffrey Roberts, M.Ed